JP2023509373A5 - - Google Patents

Info

Publication number
JP2023509373A5
JP2023509373A5 JP2022537428A JP2022537428A JP2023509373A5 JP 2023509373 A5 JP2023509373 A5 JP 2023509373A5 JP 2022537428 A JP2022537428 A JP 2022537428A JP 2022537428 A JP2022537428 A JP 2022537428A JP 2023509373 A5 JP2023509373 A5 JP 2023509373A5
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509373A (ja
JP7758672B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/060539 external-priority patent/WO2021126435A1/en
Publication of JP2023509373A publication Critical patent/JP2023509373A/ja
Publication of JP2023509373A5 publication Critical patent/JP2023509373A5/ja
Application granted granted Critical
Publication of JP7758672B2 publication Critical patent/JP7758672B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537428A 2019-12-20 2020-11-13 抗インターロイキン-23 p19抗体およびそれの使用方法 Active JP7758672B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951231P 2019-12-20 2019-12-20
US62/951,231 2019-12-20
PCT/US2020/060539 WO2021126435A1 (en) 2019-12-20 2020-11-13 Anti-interleukin-23 p19 antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023509373A JP2023509373A (ja) 2023-03-08
JP2023509373A5 true JP2023509373A5 (cg-RX-API-DMAC7.html) 2023-11-20
JP7758672B2 JP7758672B2 (ja) 2025-10-22

Family

ID=73790243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537428A Active JP7758672B2 (ja) 2019-12-20 2020-11-13 抗インターロイキン-23 p19抗体およびそれの使用方法

Country Status (8)

Country Link
US (2) US11396541B2 (cg-RX-API-DMAC7.html)
EP (1) EP4077378A1 (cg-RX-API-DMAC7.html)
JP (1) JP7758672B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220143005A (cg-RX-API-DMAC7.html)
CN (1) CN115135671B (cg-RX-API-DMAC7.html)
AU (1) AU2020409124A1 (cg-RX-API-DMAC7.html)
CA (1) CA3164996A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021126435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3230426A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen
CN115785267B (zh) * 2021-09-10 2023-12-15 三优生物医药(上海)有限公司 一种靶向IL-23p19的抗体或其抗原结合片段及其应用
WO2025036280A1 (zh) * 2023-08-11 2025-02-20 信达生物制药(苏州)有限公司 既往接受生物制剂治疗斑块状银屑病的受试者转用抗IL23p19抗体治疗斑块状银屑病的方法
CN120025436B (zh) * 2025-01-17 2025-11-18 暨南大学 一种靶向白细胞介素-23 p19亚基的单克隆抗体及其应用
CN122302052A (zh) * 2026-05-28 2026-06-30 星锐医药(苏州)有限公司 靶向il23的抗体及其构建的双抗

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
US7747677B2 (en) 2005-08-03 2010-06-29 Bea Systems, Inc. System and method for control tree optimization
ME02705B (me) 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
GB201013975D0 (en) * 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
KR102049223B1 (ko) * 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항-il-23 항체
CN102469482A (zh) 2010-11-12 2012-05-23 中兴通讯股份有限公司 一种广播控制信道信息倒换方法及系统
WO2013063391A2 (en) 2011-10-28 2013-05-02 Trianni, Inc. Transgenic animals and methods of use
CN109206516A (zh) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 抗IL-23p19抗体
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
WO2017035252A1 (en) 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
MX2018003376A (es) * 2015-09-17 2018-08-15 Amgen Inc Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
EP4414484A3 (en) 2016-02-04 2025-01-15 Trianni, Inc. Enhanced production of immunoglobulins
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物

Similar Documents

Publication Publication Date Title
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2024109678A5 (cg-RX-API-DMAC7.html)
JP2023002562A5 (cg-RX-API-DMAC7.html)
JP2023504572A5 (cg-RX-API-DMAC7.html)
JP2021514664A5 (cg-RX-API-DMAC7.html)
JP2022512132A5 (cg-RX-API-DMAC7.html)
JP2023526774A5 (cg-RX-API-DMAC7.html)
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
JP2021521843A5 (cg-RX-API-DMAC7.html)
JP2020525032A5 (cg-RX-API-DMAC7.html)
JP2015163068A5 (cg-RX-API-DMAC7.html)
JP2020522280A5 (cg-RX-API-DMAC7.html)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2020522281A5 (cg-RX-API-DMAC7.html)
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2024518776A5 (cg-RX-API-DMAC7.html)
JP2024532485A5 (cg-RX-API-DMAC7.html)
JP2024024114A5 (cg-RX-API-DMAC7.html)
JP2023506465A5 (cg-RX-API-DMAC7.html)
JP2025508066A5 (cg-RX-API-DMAC7.html)
JP2016518333A5 (cg-RX-API-DMAC7.html)
JP2020522488A5 (cg-RX-API-DMAC7.html)
JP2023510982A5 (cg-RX-API-DMAC7.html)
JP2023182689A5 (cg-RX-API-DMAC7.html)
JP2020533965A5 (cg-RX-API-DMAC7.html)